A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: distinct (21), definite (15), clear (571)

Gender pay gap report 2024

Description
Gender Pay Gap. Our Gender Pay Gap at a Glance Snapshot from 31st March 2024 Our mean average gender pay gap at UHS has reduced by 7.6% since
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Gender-pay-gap-report-2024.pdf

Gender pay gap report 2023

Description
Gender Pay Gap. Our Gender Pay Gap at a Glance Snapshot from 31st March 2023 Our mean average gender pay gap at UHS has reduced by 6.4% since
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Gender-pay-gap-report-2023.pdf

Papers Trust Board - 27 July 2023

Description
Date Time Location Chair Agenda Trust Board – Open Session 27/07/2023 9:00 - 13:15 Conference Room, Heartbeat/Microsoft Teams
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Papers-Trust-Board-27-July-2023.pdf

Vismodegib

Description
Chemotherapy Protocol BASAL CELL CARCINOMA (BCC) VISMODEGIB Regimen  BCC - Vismodegib Indication  The patient either has; a. Gorlin Syndrome with
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Vismodegib.pdf

Vinorelbine (oral day 1, 8 and 15)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1, 8, 15) This protocol may requir
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday18and15ver11.pdf

Vinorelbine (oral day 1 and 8)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1 and 8) This protocol may require
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday1and8ver11.pdf

MyelomaMPVBortezomib(SC)MelphalanPrednisolone(35day)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPV (SC)-BORTEZOMIB (SC)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple My
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibSCMelphalanPrednisolone35dayVer1.pdf

MyelomaMPVBortezomib(IV)MelphalanPrednisolone(35day)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPV (IV)-BORTEZOMIB (IV)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple My
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibIVMelphalanPrednisolone35dayVer1.pdf

Niraparib

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCERS Regimen NIRAPARIB • Ovarian Cancer – Niraparib Indication • Niraparib is recommended as maintenance
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Niraparib.pdf

SHAPE Award Guide

Description
SHAPE FUNDING AWARDS Southampton Academy of Research (SoAR) in collaboration with Applied Research Collaboration (ARC Wessex) 1. Internship Awards 2. Transitional/ Bridging Awards 3. Post Doctoral Awards Year 2020/ 2021 Contents Introduction:........................................................................................................................................... 2 Internship Award......................................................................................................
Url
/Media/Southampton-Clinical-Research/Downloads/SHAPE-Award-Guide.pdf
111 to 120 of 155
Previous … 10 11 12 13 14 … Next